Group 1 - The core point of the announcement is that the company’s subsidiary, Lijun Pharmaceutical Group Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for the domestic production registration of JP-1366 tablets, which are indicated for gastroesophageal reflux disease [1][2] Group 2 - JP-1366 tablets are an innovative potassium-competitive acid blocker (P-CAB) that effectively inhibits gastric acid secretion, promoting esophageal mucosal healing and improving reflux symptoms [2][3] - A Phase III clinical study has been initiated to compare JP-1366 tablets with Esomeprazole magnesium enteric-coated tablets in Chinese patients with gastroesophageal reflux disease, involving 362 patients [2] - The clinical study results indicate that JP-1366 tablets achieve a mucosal healing rate comparable to Esomeprazole within 8 weeks and significantly improve symptoms such as heartburn and reflux [2][3] Group 3 - The market for P-CABs in China is projected to reach approximately RMB 1.25 billion in 2024, reflecting a year-on-year growth of 81.22% from 2023 [4] - The first quarter of 2025 is expected to see P-CAB sales of around RMB 394.35 million, marking an 81.63% increase compared to the first quarter of 2024 [4] - The introduction of JP-1366 tablets will enhance the company’s product pipeline in the gastrointestinal field, providing more comprehensive treatment options [4]

Core Viewpoint - Jiangsu Hechen Pharmaceutical Co., Ltd. has had its application for the market launch of Ilaprazole enteric-coated tablets accepted, indicating a growing competition in the proton pump inhibitor (PPI) market, which is currently valued at over 15 billion yuan [1][4]. Group 1: Market Dynamics - The Ilaprazole enteric-coated tablet market has seen significant growth, surpassing 10 billion yuan after being included in the national medical insurance in 2019, with sales stabilizing above 15 billion yuan from 2021 to 2022, and slightly declining to around 13 billion yuan in 2023-2024 [4][18]. - The PPI market in 2024 is expected to be competitive, with Ilaprazole's injection ranking first and the enteric-coated tablet among the top three, showcasing its strong market presence [6]. - The competitive landscape for Ilaprazole is shifting from a single dominant player to multiple competitors, as various companies have submitted applications for generic versions [18]. Group 2: Regulatory and Competitive Landscape - The application for Ilaprazole enteric-coated tablets has been classified as a generic drug, with several companies, including Zhejiang Haoge Pharmaceutical and Jiangsu Hechen Pharmaceutical, involved in the approval process [2][10]. - The first generic application was submitted by Shijiazhuang Zhongnuo Pharmaceutical in October 2023, with expectations for approval in February 2025, marking the beginning of intensified competition in the generic market [8][12]. - A total of 13 companies have submitted applications for Ilaprazole enteric-coated tablets, indicating a robust interest in this segment of the pharmaceutical market [12][14]. Group 3: Intellectual Property and Innovation - The patents for Ilaprazole compound and enteric-coated tablets have expired, allowing for increased competition in the market, while other formulations like Ilaprazole injections have patents expiring in 2036 and micro-pellets in 2040 [14][16]. - The ongoing competition in the PPI market is expected to drive improvements in drug accessibility and quality, benefiting patients through enhanced treatment options [18].